celastrol has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, W; Chang, S; Gao, L; Hou, J; Lan, X; Li, B; Shi, J; Wang, H; Wang, Y; Wu, X; Xie, B; Xie, Y; Xu, Z; Yu, D; Zhang, Y; Zhu, W | 1 |
1 other study(ies) available for celastrol and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Pentacyclic Triterpenes; Triterpenes; Xenograft Model Antitumor Assays | 2018 |